1h Free Analyst Time
SummarySpeak directly to the analyst to clarify any post sales queries you may have.
The latest Pharmaceutical and Healthcare disease pipeline guide Atherosclerosis - Pipeline Review, H2 2020, provides an overview of the Atherosclerosis (Cardiovascular) pipeline landscape.
Atherosclerosis (or arteriosclerotic vascular disease) is a condition where the arteries become narrowed and hardened due to an excessive build up of plaque around the artery wall. The disease disrupts the flow of blood around the body, posing serious cardiovascular complications. Symptoms of atherosclerosis are chest pain (angina), pain in the leg, arm, and anywhere else that an artery is blocked, shortness of breath, fatigue, confusion (if the blockage affects circulation to the brain) and muscle weakness in the legs from lack of circulation.
Report Highlights
The Pharmaceutical and Healthcare latest pipeline guide Atherosclerosis - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Atherosclerosis (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Atherosclerosis (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Atherosclerosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 5, 8, 1, 1, 35, 14 and 2 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 19 and 2 molecules, respectively.
Atherosclerosis (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Atherosclerosis (Cardiovascular).
- The pipeline guide reviews pipeline therapeutics for Atherosclerosis (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Atherosclerosis (Cardiovascular) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Atherosclerosis (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Atherosclerosis (Cardiovascular)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Atherosclerosis (Cardiovascular).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Atherosclerosis (Cardiovascular) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
- Introduction
- Atherosclerosis - Overview
- Atherosclerosis - Therapeutics Development
- Atherosclerosis - Therapeutics Assessment
- Atherosclerosis - Companies Involved in Therapeutics Development
- Atherosclerosis - Drug Profiles
- Atherosclerosis - Dormant Projects
- Atherosclerosis - Discontinued Products
- Atherosclerosis - Product Development Milestones
- Appendix
List of Tables
- Number of Products under Development for Atherosclerosis, H2 2020
- Number of Products under Development by Companies, H2 2020
- Number of Products under Development by Universities/Institutes, H2 2020
- Products under Development by Companies, H2 2020
- Products under Development by Universities/Institutes, H2 2020
- Number of Products by Stage and Target, H2 2020
- Number of Products by Stage and Mechanism of Action, H2 2020
- Number of Products by Stage and Route of Administration, H2 2020
- Number of Products by Stage and Molecule Type, H2 2020
- Atherosclerosis - Pipeline by 13therapeutics Inc, H2 2020
- Atherosclerosis - Pipeline by Abcentra LLC, H2 2020
- Atherosclerosis - Pipeline by ABIONYX Pharma SA, H2 2020
- Atherosclerosis - Pipeline by AdaptVac ApS, H2 2020
- Atherosclerosis - Pipeline by Allysta Pharmaceuticals Inc, H2 2020
- Atherosclerosis - Pipeline by Amgen Inc, H2 2020
- Atherosclerosis - Pipeline by Annexin Pharmaceuticals AB, H2 2020
- Atherosclerosis - Pipeline by AptaBio Therapeutics Inc, H2 2020
- Atherosclerosis - Pipeline by Artery Therapeutics Inc, H2 2020
- Atherosclerosis - Pipeline by Asdera LLC, H2 2020
- Atherosclerosis - Pipeline by AstraZeneca Plc, H2 2020
- Atherosclerosis - Pipeline by Athera Biotechnologies AB, H2 2020
- Atherosclerosis - Pipeline by Auxagen Inc, H2 2020
- Atherosclerosis - Pipeline by Band Therapeutics LLC, H2 2020
- Atherosclerosis - Pipeline by BBN Cardio Therapeutics, H2 2020
- Atherosclerosis - Pipeline by Boehringer Ingelheim International GmbH, H2 2020
- Atherosclerosis - Pipeline by Centeer BioTherapeutics Ltd Co, H2 2020
- Atherosclerosis - Pipeline by CohBar Inc, H2 2020
- Atherosclerosis - Pipeline by Corbus Pharmaceuticals Inc, H2 2020
- Atherosclerosis - Pipeline by General Regeneratives Shanghai Ltd, H2 2020
- Atherosclerosis - Dormant Projects, H2 2020
- Atherosclerosis - Discontinued Products, H2 2020
List of Figures
- Number of Products under Development for Atherosclerosis, H2 2020
- Number of Products under Development by Companies, H2 2020
- Number of Products under Development by Universities/Institutes, H2 2020
- Number of Products by Top 10 Targets, H2 2020
- Number of Products by Stage and Top 10 Targets, H2 2020
- Number of Products by Top 10 Mechanism of Actions, H2 2020
- Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020
- Number of Products by Routes of Administration, H2 2020
- Number of Products by Stage and Routes of Administration, H2 2020
- Number of Products by Top 10 Molecule Types, H2 2020
- Number of Products by Stage and Top 10 Molecule Types, H2 2020
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- 13therapeutics Inc
- Abcentra LLC
- ABIONYX Pharma SA
- AdaptVac ApS
- Allysta Pharmaceuticals Inc
- Amgen Inc
- Annexin Pharmaceuticals AB
- AptaBio Therapeutics Inc
- Artery Therapeutics Inc
- Asdera LLC
- AstraZeneca Plc
- Athera Biotechnologies AB
- Auxagen Inc
- Band Therapeutics LLC
- BBN Cardio Therapeutics
- Boehringer Ingelheim International GmbH
- Centeer BioTherapeutics Ltd Co
- CohBar Inc
- Corbus Pharmaceuticals Inc
- General Regeneratives Shanghai Ltd
- GenKyoTex SA
- Grindeks AS
- Innolife Co Ltd
- Inotrem SA
- Inspyr Therapeutics Inc
- Iproteos SL
- Jenrin Discovery Inc
- Kaleido Biosciences Inc
- KineMed Inc
- Kowa Co Ltd
- LipimetiX Development Inc
- MetiMedi Pharmaceuticals Co Ltd
- MetrioPharm AG
- Mperia Therapeutics Inc
- Novartis AG
- NuSirt Biopharma Inc
- Omeros Corp
- Pharmahungary Group
- Regeneron Pharmaceuticals Inc
- Repair Biotechnologies Inc
- Riparian Pharmaceuticals Inc
- Sansho Co Ltd
- Serene LLC
- Shanghai Henlius Biotech Inc
- Shin Poong Pharm Co Ltd
- Signablok Inc
- Takeda Pharmaceutical Co Ltd
- Tiara Pharmaceuticals Inc
- Underdog Pharmaceuticals Inc
- Vascular Biogenics Ltd
- VasoRx Inc
- VasThera Co Ltd
- Vaxil Bio Therapeutics Ltd
- Vicore Pharma AB
- Wooridul Pharmaceutical Ltd
- XBiotech Inc
